SCNX Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeValuation
- Forward P/E
- 21.83
- PEG ratio
- —
- P/B
- 0.23
- P/S (TTM)
- 32.99
- EV/EBITDA
- -1.56
Profitability & growth
- ROE (TTM)
- -56.6%
- Operating margin
- -6231.0%
- Revenue growth YoY
- 449.1%
- Dividend yield
- —
- Beta
- —
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Scienture Holdings, Inc.
Company profileScienture Holdings, Inc. (SCNX) is a biotechnology company dedicated to revolutionizing the treatment of neurological disorders through its innovative drug development pipeline and experienced research team. With a strong commitment to addressing critical unmet medical needs, the company is positioned to improve patient outcomes while adeptly managing the complexities of regulatory pathways. Scienture's focus on scientific rigor, coupled with strategic partnerships, enhances its growth potential and solidifies its role as a significant player in the global healthcare market. As demand for…
Classification
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 20 AUSTIN BOULEVARD, COMMACK, NY
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer